Asahi Of Japan, NxStage Of U.S. In Pact To Market Dialysis Devices
This article was originally published in PharmAsia News
Executive SummaryJapan's Asahi Kasei Kuraray Medical and U.S.-based NxStage Medical have signed an exclusive licensing agreement for Asahi to produce and market NxStage devices in Asia. The pact also allows Asahi to market the devices in the rest of the world, but without exclusivity. The devices involved are disposable medical equipment used in home kidney dialysis. NxStage retained all rights to the equipment in North America. (Click here for more
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.